GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of is it normal to get constipation at week 7 — 50 comments in the full submission. View in context.
778
c/survodutide·submitted 1 months ago by u/cato_batista

is it normal to get constipation at week 7

Trial Databranch of 8 comments

is it normal to get constipation at week 7, logged the same way every week so the comparison is at least internally fair. Assumed the weight numbers were the point and was corrected. They are secondary to what this is being developed for. Independent purity results for this compound are very sparse across the whole…

Read the full submission and all 50 comments →

This branch

8 comments, started 1 months ago
u/elin_tamm57 points·1 months ago

Histological endpoints in this field are scored on biopsy: resolution of steatohepatitis without worsening of fibrosis, or improvement in fibrosis without worsening of steatohepatitis. Both are harder to achieve and to interpret than an imaging surrogate.

replysharereportpermalink
u/vitamin_d_void0 points·1 months ago

What does the tolerability table say at that dose?

replysharereportpermalink
[deleted]41 points·1 months ago

[deleted]

replysharereportpermalink
u/honest_syringe_pls34 points·1 months ago·edited

Not convinced. Imaging-based fat fraction is not the same as a histological response and the paper is explicit about that.

replysharereportpermalink
u/cato_batistaOP19 points·1 months ago

Correction: that is the imaging endpoint, not the histological one. The paper reports both and they differ substantially.

replysharereportpermalink
u/thermal_mass_tom14 points·1 months ago

MASH endpoints are histological, which is a much harder bar

replysharereportpermalink
u/zeynep_ndiaye9 points·1 months ago

research material is not approved for human use, which is why the clinical record here is thin

replysharereportpermalink
u/julia_mensa-7 points·1 months ago

Went slowly because everything published describes a deliberate escalation. That is the extent of what I will say about it.

replysharereportpermalink

← back to the whole thread

About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/survodutide
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/liver_enzyme_lizu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →